Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Angle Share News (AGL)
AGL Share
Price
AGL Share
News
AGL Share
Chat
AGL Share
Trades37
AGL
Live RNS
AGL Share
Charts
AGL Broker
Ratings
AGL Directors
Deals
AGL Financial
Diary
AGL
Fundamentals
AGL Short
Positions
AGL
Media
AGL Company
Research
AGL Company
Timeline
- There is currently no data for AGL
IN BRIEF: Angle highlights supportive data for DNA analysis tool
Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.
Current stock price: 17.85 pence, down 8.5% in London on Monday
12-month change: down 42%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Latest AGL News
- Angle Notes Queen Mary University's European Cancer Prognosis Patent
4 Oct 2019 - Angle Reports Positive Study Results For Parsortix System
4 Sep 2019 - Angle Ovarian Cancer Testing Platform Study Enrols First Patients
29 Aug 2019 - Angle initiates main phase of ovarian cancer clinical study
29 Aug 2019 - Angle's Parsortix Used For Analysis Of Circulating Tumor Cells
22 Jul 2019 - Angle looks to strengthen balance sheet and extend runway via placement
25 Jun 2019 - Angle upbeat on recent cancer research results
21 Jun 2019 - Angle's Parsortix Successfully Investigates Immunotherapy Target
21 Jun 2019
Related News
IN BRIEF: Angle names Peter Collins as interim CEO
(Alliance News) - Angle PLC - Guildford, England-based liquid biopsy company, which is to be renamed CelLBxHealth PLC - Appoints Peter Collins as inte...
Angle touts planned name and strategy change, Groen turns executive
(Alliance News) - Angle PLC shares fell on Wednesday, after it announced plans to rename itself CelLBxHealth PLC and "[pursue] a revised strategy", wi...
IN BRIEF: Angle CEO and finance lead step down after shareholder talks
Angle PLC - Guildford, England-based liquid biopsy company - Says that, following talks with an unnamed "significant shareholder", Chief Executive Off...
Angle News
Angle Notes Queen Mary University's European Cancer Prognosis Patent
Angle Notes Queen Mary University's European Cancer Prognosis Patent
Angle Reports Positive Study Results For Parsortix System
(Alliance News) - Angle PLC on Wednesday noted positive results from a study of its Parsortix system in small cell lung cancer.Parsortix is Angle's li...
Angle Ovarian Cancer Testing Platform Study Enrols First Patients
(Alliance News) - Liquid biopsy firm Angle PLC said Thursday the first patients for its ovarian cancer test study have been enrolled ahead of anticipa...
Angle initiates main phase of ovarian cancer clinical study
(Sharecast News) - Liquid biopsy company Angle announced on Friday that the main phase of its 200-patient ovarian cancer clinical verification study h...
Angle's Parsortix Used For Analysis Of Circulating Tumor Cells
(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done ...
Angle looks to strengthen balance sheet and extend runway via placement
(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to stre...
Angle upbeat on recent cancer research results
(Sharecast News) - Liquid biopsy company Angle announced on Friday that the University Medical Centre Hamburg-Eppendorf (UKE) cancer centre has publis...
Angle's Parsortix Successfully Investigates Immunotherapy Target
(Alliance News) - Angle PLC on Friday said its Parsortix system has been successfully used as a liquid biopsy to investigate an immunotherapy target i...
Follow the stocks
